Baird Financial Group
FOMX

Baird Financial Group’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Baird Financial Group’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-37,988
Closed -$188K – 1271
2017
Q1 		$188K Buy
+37,988
New +$366K ﹤0.01% 1173
2016
Q3 		– Sell
-58,964
Closed -$374K – 1237
2016
Q2 		$374K Sell
58,964
-25,170
-30% -$167K ﹤0.01% 989
2016
Q1 		$549K Hold
84,134
– – 0.01% 898
2015
Q4 		$682K Buy
84,134
+69,134
+461% +$517K 0.01% 817
2015
Q3 		$110K Hold
15,000
– – ﹤0.01% 1201
2015
Q2 		$154K Buy
+15,000
New +$166K ﹤0.01% 1248

Other funds holding FOMX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Baird Financial Group's FOMX Position: Q2 2017 in Review

Baird Financial Group sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q2 2017, closing a stake of 37,988 shares — an estimated $188K sold.

Baird Financial Group first reported a position in FOMX in Q2 2015 and held it in 6 quarters. The position peaked at $682K in Q4 2015. 56 funds tracked by Wall St. Rank hold FOMX as of Q2 2017.

  • Baird Financial Group reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q2 2017 after selling out during the quarter.
  • Baird Financial Group sold 37,988 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q2 2017, an estimated $188K.
  • Baird Financial Group first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 6 quarters.
  • Baird Financial Group's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $682K in Q4 2015.
  • 56 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q2 2017.

Based on Baird Financial Group's 13F filing for Q2 2017, filed 14 Aug 2017.